Vol. 53 | No. 1 | January-June 2025 Back

Open Access

The Trojan Horse - A Case of Transthyretin Cardiac Amyloidosis Diagnosed Via Multi-Modality Imaging

Gwen R. Marcellana, Lynnette Marie C. Tan, Jared Alphonse S. Cordero, Carmen N. Chungunco, Christian Michael H. Pawhay, Nathania S. Fajardo
May 2025 DOI 10.69944/pjc.e380b387df

Abstract

Background: Observational studies have increasingly reported transthyretin amyloid cardiomyopathy (ATTR-CM) as an under-recognized cause of heart failure. We report the first ATTR-CM diagnosed via multi-modality imaging in the Philippines signifying an important milestone in recognition and management of this formerly believed rare disease, locally. Utilization of non-invasive imaging such as echocardiography, cardiac MRI and technetium-99m pyrophosphate scintigraphy (PYP) demonstrates the potential for accurate diagnosis as well as timely and appropriate treatment strategies.

Discussion: An 81/M Filipino with a history of carpal tunnel surgery, post-percutaneous coronary intervention (PCI), had three months’ history of refractory heart failure symptoms despite optimized medical treatment. His 2D-echo showed an ejection fraction (EF): 45%-50%, increased left ventricular (LV) posterior wall thickness with mild basal inferior wall hypokinesia and ECG: atrial fibrillation with low voltage. Speckle tracking imaging showed average global longitudinal strain: - 6.5% with cherry-on-top pattern on polar strain map. Cardiac MRI demonstrated diffuse late gadolinium enhancement from endocardial to transmural layers of biventricular and biatrial walls, highly suggestive of cardiac amyloidosis (CA). Light-chain amyloidosis was excluded by negative serum/urine protein electrophoresis/immunofixation. Tc-99m PYP scan revealed greater myocardial-than-bone uptake with a Perugini score 3 and calculated heart-to-contralateral ratio of 1.7. Congestion was controlled with intravenous loop diuretics and he was discharged stable with metoprolol succinate, dapagliflozin and apixaban. At the time of paper submission, he is currently being evaluated for tafamidis treatment.

Conclusion: The case highlighted the advantage of multi-modality imaging for noninvasive yet accurate identification of the disease. A tailored approach is required in slowing the disease progression and improving outcomes.

References
  1.  Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail [Internet]. 2022;24(12):2342–51. Available from: http://dx.doi.org/10.1002/ejhf.2532
  2. Writing Committee, Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol [Internet]. 2023;81(11):1076–126. Available from: http://dx.doi.org/10.1016/j.jacc.2022.11.022
  3. Papingiotis’ [’georgios, Basmpana’ ’lamprini, Farmakis’] ’dimitrios. Cardiac amyloidosis: epidemiology, diagnosis and therapy [Internet]. Escardio.org. [cited 2025 Mar 20]. Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/cardiac-amyloidosis-epidemiology-diagnosis-and-therapy  
  4. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation [Internet]. 2016;133(24):2404–12. Available from: http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612
  5. Khalil H, Alzahrani T. Cardiomyopathy imaging. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541056/
  6. Kiotsekoglou A, Saha SK, Nanda NC, Lindqvist P. Echocardiographic diagnosis of cardiac amyloidosis: Does the masquerader require only a “cherry on top”? Echocardiography [Internet]. 2020;37(11):1713–15. Available from: http://dx.doi.org/10.1111/echo.14952
  7. Aquaro GD, De Gori C, Faggioni L, Parisella ML, Cioni D, Lencioni R, et al. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl [Internet]. 2023;25(Suppl C):C130–36. Available from: http://dx.doi.org/10.1093/eurheartjsupp/suad015; PMCID: PMC10132607.
  8. Galat A, Rosso J, Guellich A, Van Der Gucht A, Dubois-Randé J-L, Plante-Bordeneuve V, et al. Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Orphanet J Rare Dis [Internet]. 2015;10(S1):P49. Available from: http://dx.doi.org/10.1186/1750-1172-10-s1-p49
  9. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail [Internet]. 2019;7(8):709–16. Available from: http://dx.doi.org/10.1016/j.jchf.2019.04.010.
  10. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med [Internet]. 2018;379(11):1007–16. Available from: http://dx.doi.org/10.1056/NEJMoa1805689.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.